AssuredPartners Investment Advisors LLC Purchases Shares of 29,611 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

AssuredPartners Investment Advisors LLC purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 29,611 shares of the company's stock, valued at approximately $312,000.

A number of other large investors also recently made changes to their positions in SPRY. Raymond James Financial Inc. purchased a new position in shares of ARS Pharmaceuticals in the 4th quarter worth $6,576,000. Peregrine Capital Management LLC acquired a new stake in ARS Pharmaceuticals during the 4th quarter worth approximately $4,469,000. Jacobs Levy Equity Management Inc. raised its holdings in ARS Pharmaceuticals by 78.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 653,048 shares of the company's stock valued at $9,469,000 after buying an additional 288,021 shares during the period. Miura Global Management LLC acquired a new position in ARS Pharmaceuticals during the third quarter valued at approximately $3,915,000. Finally, Wexford Capital LP acquired a new stake in shares of ARS Pharmaceuticals in the third quarter worth $3,601,000. Hedge funds and other institutional investors own 68.16% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Scotiabank started coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective on the stock. Leerink Partners increased their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Oppenheimer began coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They issued an "outperform" rating and a $40.00 price target for the company. William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Finally, Raymond James raised their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, January 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ARS Pharmaceuticals currently has an average rating of "Buy" and an average target price of $31.00.

Remove Ads

Insider Buying and Selling

In other news, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now owns 7,696 shares of the company's stock, valued at $107,744. This trade represents a 56.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Laura Shawver sold 50,000 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00. Following the sale, the director now directly owns 210,346 shares of the company's stock, valued at approximately $2,589,359.26. This represents a 19.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 159,600 shares of company stock worth $1,866,516. 40.10% of the stock is owned by company insiders.

ARS Pharmaceuticals Trading Up 2.8 %

Shares of ARS Pharmaceuticals stock traded up $0.35 on Wednesday, reaching $12.88. 622,827 shares of the company were exchanged, compared to its average volume of 1,078,559. ARS Pharmaceuticals, Inc. has a fifty-two week low of $7.55 and a fifty-two week high of $18.51. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -25.35 and a beta of 1.03. The stock has a fifty day moving average price of $12.13 and a 200-day moving average price of $13.09.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.56. The firm had revenue of $86.58 million for the quarter, compared to analysts' expectations of $15.46 million. On average, equities analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.